Gabapentin: The precise mechanisms by which gabapentin produces its analgesic and antiepileptic actions are unknown. Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, o r degradation. I n vitro studies have shown that gabapentin binds with high-affinity t o the a2 subunit o f voltage activated calcium channels; however, the relationship of this binding t o the therapeutic effects o f gabapentin is unknown.
Amitriptyline: Amitriptyline is a dibenzo cycloheptadiene tricyclic antidepressant. I t increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake o f norepinephrine and serotonin. Amitriptyline is metabolized to nortriptyline which inhibits the reuptake of norepinephrine and serotonin almost equally. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically this action may potentiate o r prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with the reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.
Indication:
- Neuropathic pain (pain from nerve damage)
- Diabetic nerve pain (painful diabetic neuropathy)
- Postherpetic neuralgia (pain after shingles)
- Chronic nerve pain from spinal cord injury or other causes
- May assist in fibromyalgia management and improve sleep quality for chronic pain patients.
- They are commonly prescribed for chronic pain syndromes, especially when conventional analgesics fail or for conditions with both positive and negative neurological symptoms.
Clinical Advantages
- Gabapentin demonstrates good efficacy in neuropathic pain conditions, with pooled clinical trial analyses showing significant reductions in pain intensity. The number needed to treat (NNT) for substantial relief ranges from approximately 6 to 8 depending on condition, and its safety profile is favourable, with a high number needed to harm (NNH).
- Amitriptyline is recommended as a first-line therapy for pain associated with diabetic neuropathy by major international pain societies. NNT for 50% pain relief is around 1.3, indicating high effectiveness.
Both agents offer versatility for oral administration and can be used either as monotherapy or in combination for enhanced pain control, with dosing individualized for clinical response and tolerability.
